Related Experiment Videos
[Perioperative β-adrenergic blocking agents and postoperative prognosis]
Hideaki Tsuchida1, Masahiro Kida
1Department of Anesthesiology and Perioperative Medicine, Kanazawa Medical University, Ishikawa 920-0293.
Masui. the Japanese Journal of Anesthesiology
|June 19, 2012
Summary
Perioperative myocardial ischemia, a frequent postoperative complication, carries a poor prognosis. Prompt medical treatment and vigilant monitoring are crucial for high-risk patients, especially the elderly.
Area of Science:
- Cardiology
- Anesthesiology
- Geriatric Medicine
Context:
- Perioperative myocardial ischemia is a common yet often asymptomatic complication within 48 hours post-surgery.
- Patients with cardiac risk factors require close monitoring until the second postoperative day.
- Elderly patients are particularly susceptible to perioperative cardiac events and cerebral infarction.
Purpose:
- To highlight the significance of perioperative myocardial ischemia and its management.
- To emphasize the need for prompt medical intervention based on the cause of sympathetic nervous system activation.
- To provide guidance on the use of beta-adrenergic blocking agents and blood pressure management in surgical patients.
Summary:
- Perioperative myocardial ischemia frequently occurs postoperatively with a poor prognosis and few symptoms.
- Anesthesiologists must monitor high-risk patients closely and initiate prompt medical treatment.
- Continuing or resuming beta-adrenergic blocking agents and managing blood pressure are key considerations, especially in elderly patients.
Impact:
- Improved patient outcomes through timely diagnosis and management of perioperative myocardial ischemia.
- Enhanced perioperative care protocols for patients undergoing noncardiac surgery.
- Increased awareness among clinicians regarding the risks and management strategies for cardiac events in the postoperative period.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
01:28Cardiomyopathy VII: Pre and Post Operative Nursing Management
Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but nonselective agent, paving the way...